amifampridine has been researched along with Muscular Atrophy in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Muscular Atrophy: Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morbiato, L | 1 |
| Carli, L | 1 |
| Johnson, EA | 1 |
| Montecucco, C | 1 |
| Molgó, J | 1 |
| Rossetto, O | 1 |
1 other study available for amifampridine and Muscular Atrophy
| Article | Year |
|---|---|
Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Botulinum Toxins, Type A; Drug Resistance | 2007 |